Key Takeaways
- The FDA issued dozens of warning letters in early June 2026 over marketing of compounded GLP‑1s by telehealth firms.
- Companies implied their compounded versions of semaglutide and tirzepatide matched FDA‑approved drugs or came from “FDA‑approved” pharmacies.
- Compounded GLP‑1s are not reviewed or approved by FDA, and marketing them as equivalent violates federal law.
What did the FDA say about compounded GLP‑1s?
In early June 2026, the FDA issued warning letters to telehealth companies making misleading claims about compounded GLP‑1s. The agency flagged claims that these compounded products were the same or equivalent to FDA‑approved drugs such as Wegovy®, Ozempic®, Zepbound™, and Mounjaro®. The FDA also noted that compounding pharmacies and outsourcing facilities are not “FDA‑approved” or “FDA‑licensed” entities. Compounded GLP‑1s receive no FDA evaluation for safety, effectiveness, or quality before marketing—presenting them as such violates the FD&C Act [502(a) and 502(bb)] and constitutes misbranding (fda.gov).
How widespread was the enforcement in June?
Early June saw the FDA target many telehealth companies. At least five letters dated June 8, 2026, went to Maximus Health Inc., Trinity HealthCare Supply (altRx), Glow Medispa (Mint Med), Ezra Holdco (Ezra), and Public Health Solution (DrMedHealth) (metabolicledger.com). The FDA issued a total of 25 warning letters in early June against telehealth companies marketing compounded GLP‑1 copycats (news.bloomberglaw.com).
Why is the FDA acting now?
The FDA had already warned in March 2026, sending 30 letters to telehealth firms making false claims about compounded GLP‑1s (content.govdelivery.com). In February, the agency announced it would restrict GLP‑1 active pharmaceutical ingredients intended for mass‑marketing of unapproved compounded drugs, especially when promoted as alternatives to FDA‑approved options (fda.gov). Supply of brand‑name GLP‑1 drugs has stabilized, narrowing the narrow exceptions under sections 503A and 503B for compounding. Compounded versions must not duplicate commercially available drugs in strength or route of administration (fda.gov).
FAQ
What are compounded GLP‑1s?
Compounded GLP‑1s are semaglutide or tirzepatide formulations mixed by compounding pharmacies or outsourcing facilities. They are not approved by FDA and receive no evaluation for safety, effectiveness, or quality before marketing.
Why did the FDA issue warning letters to telehealth companies?
The FDA flagged misleading marketing. Companies implied their compounded GLP‑1s were equivalent to FDA‑approved drugs or sourced from “FDA‑approved” pharmacies, which violates federal law.
Are compounded GLP‑1s the same as generic drugs?
No. Generic drugs must be FDA‑approved before marketing. Compounded GLP‑1s have not gone through FDA review and are not generic versions of approved drugs.
Can compounding pharmacies call themselves FDA‑approved?
No. The FDA does not approve or license compounding pharmacies or outsourcing facilities. Labeling or implying they are FDA‑approved or FDA‑licensed is false and misleading.
What should patients know about compounded GLP‑1s?
Compounded GLP‑1s are not evaluated by FDA like approved drugs. Misleading claims about their safety or equivalence can affect patient trust and safety.
Not medical advice. GLP-1 medications are prescription drugs that require clinical supervision. Talk to a licensed healthcare provider before starting, stopping, or changing any treatment.